Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a multi-center observational real-world study, with a total of 500 patients planned to be enrolled. This study is divided into two cohorts: the triple-negative breast cancer (TNBC) cohort and the hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer (HR+/ HER2-BC) cohort. The aim of this study is to assess the efficacy and safety of Sacituzumab Tirumotecan (SKB264) monotherapy or combination therapy in patients with unresectable locally advanced, recurrent or metastatic HER2-negative breast cancer in the real-world setting.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony rak piersi HER2-ujemny (bez receptora HER2)
- •Rak w stadium zaawansowanym, nawrotowy lub z przerzutami, których nie można operować
- •Wcześniej stosowano maksymalnie 2 linie leczenia chemicznego/biologicznego
- •Pacjent otrzyma lek SKB264 (sam lub z innymi lekami)
- •Dobrowolna zgoda na udział w badaniu
✗ Disqualifies
- •Inne nowotwory złośliwe (oprócz raka skóry lub raka szyjki macicy w początkowym stadium)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (19)
The Second Affiliated Hospital of Anhui Medical University
Hefei, China
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
Peking University First Hospital
Beijing, China
Chinese PLA General Hospital
Beijing, China
Fujian Cancer Hospital
Fuzhou, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
The Third People's Hospital of Zhengzhou
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Taihe Hospital
Shiyan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Hubei Cancer Hospital
Wuhan, China
The First People's Hospital of Changde City
Changde, China
The first hospital of Jilin University
Changchun, China
Yantai Yuhuangding Hospital
Yantai, China
Zhongshan Hospital Fudan University
Shanghai, China
Shanxi Bethune Hospital
Taiyuan, China
Suining Central Hospital
Suining, China
The Affiliated People's Hospital of Ningbo University
Ningbo, China
Trial contact
Xue Wang, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.